Wanbangde Pharmaceutical Holding Group Co.Ltd(002082)
Record of investor relations activities
No.: 20220302
☑ Specific object research □ analyst meeting
□ media interview □ performance briefing
Investor relations activities □ press conference □ roadshow activities
category
□ site visit
□ others (please specify other activities in words)
Name of participant and Shenwan Hongyuan Group Co.Ltd(000166) : name of Yang Jiajia, Cai Ming and Zhan Yongchang
Time: March 2, 2022
Place: company conference room
Chairman and general manager: Zhao Shouming
Secretary of the board of directors of the receptionist of the listed company: Liu Tongke
Name of securities affairs representative: Jiang Jian
1、 Company profile:
1. Industrial transformation and upgrading: after three years since 2017, the company has changed from the traditional aluminum processing and non-ferrous metal trade industry to the medical and health industry focusing on drug manufacturing and medical devices. In 2020, the company carried out the research and development of nasal spray recombinant Newcastle disease (NDV) carrier covid-19 vaccine through joint development.
2. Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Pharmaceutical Group Co., Ltd. is a core enterprise in the pharmaceutical manufacturing industry. It is a high-tech enterprise specializing in the R & D, production and sales of modern traditional Chinese medicine, chemical raw materials and their preparations. It is characterized by the investor relationship activities of natural botanical drugs, focusing on cardiovascular, cerebrovascular and nervous system drugs, respiratory system, mental system Digestive system and other fields introduce the product pattern of drug Qitou development with main contents. It is one of the pharmaceutical enterprises with more drug dosage forms and approval numbers in China. It has two core products with full intellectual property rights: huperzine a raw material and injection pioneered in the world and ginkgo leaf dropping pills, an exclusive Chinese traditional medicine protected variety in China.
Core product: Ginkgo biloba dropping pills: the standard of Ginkgo biloba extract in China is the standard of plant medicine introduced from Germany. Wanbond Ginkgo biloba dropping pills have exclusive dosage forms with independent intellectual property rights and national second-class traditional Chinese medicine protection varieties; In 2017, Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) pharmaceutical, together with experts including academicians from more than ten institutions, including China Pharmaceutical University, Zhejiang University, Chinese Academy of traditional Chinese medicine, Tianjin University of traditional Chinese medicine and Anzhen Hospital, established China’s first Collaborative Innovation Alliance for medical research enterprises of pharmaceutical products – Collaborative Innovation Alliance for medical research enterprises of ginkgo leaf dropping pills. In recent years, Chinese and foreign experts from the University of Sydney, the University of Geneva and Luohu hospital have joined the alliance to help the systematic research of Ginkgo biloba dropping pills.
Huperzine A, the leading product of nervous system, was the first product developed by two academicians at home and abroad in the 1980s. It was originally extracted from plants, and Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) pharmaceutical conquered the whole synthetic process. In the research field of huperzine A API and series of preparations, it has successively obtained invention patents from China, the United States, Japan and the European Union.
Five academicians have successively participated in the research of the product. The exclusive variety huperzine A injection has been successfully listed in 2018. The huperzine a controlled-release tablets developed in cooperation with the academician team have entered the clinical trial stage. The injection has carried out the application research of huperzine A injection in the treatment of spinal cord injury / brain injury and other diseases, and the single center open control study on reducing the occurrence of postoperative delirium in patients with MVD. It can treat postoperative brain injury and promote the intellectual recovery of patients.
The company’s characteristic API + Preparation integration mode is the core competitiveness of generic drug production. The main varieties include bromohexidine hydrochloride, phloroglucinol, clozapine, chlorpromazine, cimetidine, etc.
3. Medical device industry: the medical device business mainly includes China’s Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Medical Technology Co., Ltd., Zhejiang Kangkang medical device Co., Ltd., Zhejiang kangci Medical Technology Co., Ltd., tecmed Africa and elite surgical under Anland medical overseas, etc. It is mainly engaged in the development of high-end medical devices, medical equipment services and the provision of hospital engineering services. Its main products and services include orthopedic implant devices, medical equipment and hospital engineering services, disposable sterile medical polymer consumables and protective articles Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) medical treatment’s international development strategy of “bringing in and going out” has achieved initial results. “China Africa Medical Science and Technology Park project”, the China Africa Medical Science and Technology Park project has passed the completion acceptance in November 2020. The main industries include:
The introduction of South African orthopedic instruments has been implemented. Kangci orthopedics has moved to China Africa Industrial Park to establish an orthopedic business department. At present, 8 projects are under registration and application;
Integrate the intensive and intelligent production of polymer medical products in China, the full-automatic central feeding system, supporting full-electric injection molding machine, full-automatic roll printing, assembly, packaging wiring, full-intelligent unmanned sterilization workshop and intelligent three-dimensional warehouse, so as to improve the quality of products and target the international safety and epidemic prevention syringes. In July 2021, the installation of 10 automatic syringe production lines expanded by the company was completed, and the syringe production capacity reached 1.25 billion pieces / year. At present, the disposable sterile syringe of the company has passed the fda510 (k) certification of the United States and the CE certification of the European Union, and the self destruction syringe has passed the fda510 (k) certification of the United States. In the future, the company will carry out its own business in the international market with its own brand.
2、 Exchange Q & a session
The main contents of this exchange are as follows:
1. What is the company’s development strategy?
A: according to the development strategy of the company’s pharmaceutical health industry, the company completed the stripping of the original traditional aluminum processing industry in March 2021. At present, the main industries are pharmaceutical manufacturing and medical devices. In the future, the company will focus on the pharmaceutical and health industry.
2. What is the future development plan of the company’s pharmaceutical sector?
After years of development, Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) pharmaceutical has initially formed the industrial chain form of “coordinated layout of modern traditional Chinese medicine and chemical drugs, linkage development of characteristic APIs and preparations” and the product pattern of “featuring natural botanical drugs, dominated by drugs for cardiovascular, cerebrovascular and nervous system, and selective breakthroughs in drugs for respiratory system and other fields”.
Relying on the production advantages of existing APIs + preparations, the company will carry out the international business of APIs and preparations through self-operation or cooperation with third parties. According to the industrial layout of pharmaceutical manufacturing sector, the company will further promote the research and development of nasal spray vaccine and expand the business in the field of biopharmaceutical.
The Ginkgo biloba leaves and huperzine A products of the company are derived from Chinese herbal medicine, and there are 24 varieties of traditional Chinese medicine. In terms of traditional Chinese medicine research and development, the company has carried out strategic cooperation with yingkerui (Tianjin) innovative medicine research Co., Ltd. to jointly develop class 1.1 traditional Chinese Medicine innovative pharmacology zhongxiaopi granules. In the future, the company will adopt extended development to enrich the product structure of the company, Expand the production capacity of traditional Chinese medicine business and enhance the company’s market competitiveness.
3. What is the future development plan of the company’s medical device sector?
The company’s medical devices are mainly divided into orthopedic devices and polymer consumables. Among them, the orthopaedic device industry company will continue to promote the introduction of orthopaedic device related technologies from its South African subsidiary and the registration and certification of orthopaedic products in China. At present, the company has carried out the registration and application of orthopaedic devices in China. After the registration, the company will gradually carry out the production and listing of orthopaedic devices, replace imports, and develop China’s medium and high-end orthopaedic implant device market.
Polymer consumables industry: according to the market demand in 2021, the company completed the expansion of 10 automatic syringe production lines in July 2021. At present, the syringe production capacity reaches 1.25 billion pieces / year. The company’s disposable syringe has passed the United States
Fda510 (k) and EU CE certification. The self destruct syringe has passed the fda510 (k) certification in the United States, and the self destruct syringe has passed the fda510 (k) certification in the United States. In the future, the company will carry out its own international business with its own brand. In December 2021, the company invested and established a joint venture subsidiary to carry out light luxury mask and advertising customized mask business, and drive the original plane mask and melt blown cloth business. At present, the company’s medical surgical mask has passed the American fda510 (k) certification and is qualified to enter the American market.
Annex list (if any) none.
Date: March 2, 2022
